Abstract
Beta-adrenoceptors are predominantly located in the cerebral cortex, nucleus accumbens and striatum. At lower densities, they are also present in amygdala, hippocampus and cerebellum. Beta-2 sites regulate glial proliferation during ontogenic development, after trauma and in neurodegenerative diseases. The densities of beta-1 adrenoceptors are changed by stress, in several mood disorders (depression, excessive hostility, schizophrenia) and during treatment of patients with antidepressants. A technique for beta-adrenoceptor imaging in the human brain is not yet available. Although 24 (ant)agonists have been labeled with either 11C or 18F and some of these are successful myocardial imaging agents, only two (S-1-18Ffluorocarazolol and S-1-18F-fluoroethylcarazolol) could actually visualize ß-adrenoceptors within the central nervous system. Unfortunately, these radiopharmaceuticals showed a positive Ames test. They may be mutagenic and cannot be employed for human studies. Screening of more than 150 beta-blockers described in the literature yields only two compounds (exaprolol and L643,717) which can still be radiolabeled and evaluated for ß-adenoceptor imaging. However, other imaging techniques could be examined. Cerebral ß-adrenoceptors might be labeled after temporary opening of the blood-brain barrier (BBB) and simultaneous administration of a hydrophilic ligand such as S-11C-CGP12388. Another approach to target ß-adrenoceptor ligands to the CNS is esterification of a myocardial imaging agent (such as 11C-CGP12177), resulting in a lipophilic prodrug which can cross the BBB and is split by tissue esterases. BBB opening is not feasible in healthy subjects, but the prodrug approach may be successful and deserves to be explored.
Keywords: beta-adrenoceptors, positron emission tomography., human, brain, depression, multiple sclerosis, radiopharmaceuticals, imaging
Current Pharmaceutical Design
Title: PET Imaging of Beta-Adrenoceptors in Human Brain: A Realistic Goal or a Mirage?
Volume: 10 Issue: 13
Author(s): Aren van Waarde, Willem Vaalburg, Petra Doze, Fokko J. Bosker and Philip H. Elsinga
Affiliation:
Keywords: beta-adrenoceptors, positron emission tomography., human, brain, depression, multiple sclerosis, radiopharmaceuticals, imaging
Abstract: Beta-adrenoceptors are predominantly located in the cerebral cortex, nucleus accumbens and striatum. At lower densities, they are also present in amygdala, hippocampus and cerebellum. Beta-2 sites regulate glial proliferation during ontogenic development, after trauma and in neurodegenerative diseases. The densities of beta-1 adrenoceptors are changed by stress, in several mood disorders (depression, excessive hostility, schizophrenia) and during treatment of patients with antidepressants. A technique for beta-adrenoceptor imaging in the human brain is not yet available. Although 24 (ant)agonists have been labeled with either 11C or 18F and some of these are successful myocardial imaging agents, only two (S-1-18Ffluorocarazolol and S-1-18F-fluoroethylcarazolol) could actually visualize ß-adrenoceptors within the central nervous system. Unfortunately, these radiopharmaceuticals showed a positive Ames test. They may be mutagenic and cannot be employed for human studies. Screening of more than 150 beta-blockers described in the literature yields only two compounds (exaprolol and L643,717) which can still be radiolabeled and evaluated for ß-adenoceptor imaging. However, other imaging techniques could be examined. Cerebral ß-adrenoceptors might be labeled after temporary opening of the blood-brain barrier (BBB) and simultaneous administration of a hydrophilic ligand such as S-11C-CGP12388. Another approach to target ß-adrenoceptor ligands to the CNS is esterification of a myocardial imaging agent (such as 11C-CGP12177), resulting in a lipophilic prodrug which can cross the BBB and is split by tissue esterases. BBB opening is not feasible in healthy subjects, but the prodrug approach may be successful and deserves to be explored.
Export Options
About this article
Cite this article as:
Waarde van Aren, Vaalburg Willem, Doze Petra, Bosker J. Fokko and Elsinga H. Philip, PET Imaging of Beta-Adrenoceptors in Human Brain: A Realistic Goal or a Mirage?, Current Pharmaceutical Design 2004; 10 (13) . https://dx.doi.org/10.2174/1381612043384754
DOI https://dx.doi.org/10.2174/1381612043384754 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Late Sodium Current Inhibition: The Most Promising Antiarrhythmic Principle in the Near Future?
Current Medicinal Chemistry Tissue Doppler Imaging in Coronary Artery Diseases and Heart Failure
Current Cardiology Reviews What Does a Pediatrician Need to Know About Chronic Diarrhea?
Current Pediatric Reviews Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications
Coronaviruses Editorial: (Thematic Issue: Novel Strategies for Cardiac Repair Post-Myocardial Infarction)
Current Pharmaceutical Design Multiple Sclerosis – Established and Novel Therapeutic Approaches
Central Nervous System Agents in Medicinal Chemistry Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19
Current Stem Cell Research & Therapy Potential Therapeutic Effect of Antioxidant Therapy in Shock and Inflammation
Current Medicinal Chemistry Targeting Vascular Niche by Parathyroid Hormone
Current Medicinal Chemistry Population Pharmacogenomics and Personalized Medicine Research in Hungary: Achievements and Lessons Learned
Current Pharmacogenomics and Personalized Medicine The Impact of Opioids on Cardiac Electrophysiology
Current Cardiology Reviews Renin-Angiotensin System in Diabetes
Protein & Peptide Letters Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Risk Profiles in Type 2 Diabetes (Metabolic Syndrome): Integration of IL-10 Polymorphisms and Laboratory Parameters to Identify Vascular Damages Related Complications
Current Pharmaceutical Design Old and New Gasotransmitters in the Cardiovascular System: Focus on the Role of Nitric Oxide and Hydrogen Sulfide in Endothelial Cells and Cardiomyocytes
Current Pharmaceutical Biotechnology Comparison of High-Sensitive CRP, RDW, PLR and NLR between Patients with Chronic Obstructive Pulmonary Disease and Chronic Heart Failure
Current Respiratory Medicine Reviews PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Genetically Modified Endothelial Progenitor Cells in the Therapy of Cardiovascular Disease and Pulmonary Hypertension
Current Vascular Pharmacology Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets